Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
12
×
clinical trials
12
×
life sciences
national blog main
national top stories
biotech
boston blog main
new york blog main
boston top stories
new york top stories
san francisco blog main
san francisco top stories
fda
national
raleigh-durham blog main
raleigh-durham top stories
indiana blog main
indiana top stories
regeneron pharmaceuticals
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
detroit blog main
detroit top stories
eli lilly
glaxosmithkline
inclisiran
merck
novartis
roche
alnylam pharmaceuticals
biogen
What
drug
fda
medicines
roundup
bio
new
cholesterol
medco
pricing
approval
biotech
brings
cancer
days
decades
lowering
lung
market
medicine
migraine
news
nod
twice
wins
won
according
aces
acquire
acute
addresses
adults
advanced
advantages
agreed
akcea
allergan
alliance
amgen
amgen’s
announced
Language
unset
12
×
Current search:
amgen
×
" clinical trials "
×
unset
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More